March 17, 2000

Wall Street Again Values Biotechnology Research

By MARTIN VAN DER WERF

Universities that license new drugs and gene therapies may benefit from increased interest by venture-capital investors in biotechnology start-up companies, according to speakers last month at the annual meeting of the Association of University Technology Managers.

Wall Street is coming to believe in the market's potential, primarily because of the success of companies that are mapping the human genome, said Alan G. Walton, a general partner in Oxford

Print Subscription

Digital Subscription

Already have an account? Log In Now.